Skip to main content

Advertisement

SpringerLink
Log in

Kein zusätzlicher Vorteil durch gleichzeitige Gabe von Trastuzumab und Anthracycline

No addition benefit from coadministration of trastuzumab and anthracyclines

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Aman U, Buzdar AU, Vera J et al (2013) Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 14:1317–1325

    Article  Google Scholar 

  2. Buzdar AU, Ibrahim NK, Francis D et al (2005) Significantly higher pathologic complete remission rate after neo-adjuvant therapy with trastuzumab, paclitaxel and epiribicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor2-positive operable breast cancer. J Clin Oncol 23:3676–3685

    Article  CAS  PubMed  Google Scholar 

  3. Chavez-MacGregor M, Zhang N, Buchholz T et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222–4228

    Article  CAS  PubMed  Google Scholar 

  4. Robidoux A, Tang G, Rastogi P et al (2013) Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 14:1183–1192

    Article  CAS  PubMed  Google Scholar 

  5. Schneeweiss A, Chia S, Hickish T et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278–2284

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. M. Wilhelm gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Medizinische Klinik 5 , Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland

    M. Wilhelm

Authors
  1. M. Wilhelm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Wilhelm.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilhelm, M. Kein zusätzlicher Vorteil durch gleichzeitige Gabe von Trastuzumab und Anthracycline. Strahlenther Onkol 190, 428–429 (2014). https://doi.org/10.1007/s00066-014-0558-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-014-0558-8

Search

Navigation